Suppr超能文献

两种感觉神经肽,即P物质和降钙素基因相关肽,对犬肝动脉和门静脉血管床的作用。

The actions of two sensory neuropeptides, substance P and calcitonin gene-related peptide, on the canine hepatic arterial and portal vascular beds.

作者信息

Withrington P G

机构信息

Department of Pharmacology, Faculty of Basic Medical Sciences, Queen Mary and Westfield College, London.

出版信息

Br J Pharmacol. 1992 Oct;107(2):296-302. doi: 10.1111/j.1476-5381.1992.tb12741.x.

Abstract
  1. The two peptides, calcitonin gene-related peptide (CGRP) and substance P (SP) were administered individually as bolus injections into the separately perfused hepatic arterial and portal vascular beds of the anaesthetized dog to assess their actions and relative molar potencies at these sites. 2. CGRP caused an immediate dose-related increase in hepatic arterial flow when injected close-arterially, reflecting a fall in resistance. This vasodilator effect was slightly increased by the prior administration of the selective beta 2-adrenoceptor antagonist, ICI 118,551. 3. On a molar basis, CGRP was more potent as an hepatic arterial vasodilator than the non-selective beta-adrenoceptor agonist, isoprenaline (Iso). 4. Intra-portal injection of CGRP also evoked hepatic arterial vasodilatation unaccompanied by other cardiovascular changes. 5. CGRP in doses up to 10 nmol had no effect on portal vascular resistance when administered intra-portally. 6. SP evoked a rapid, dose-related increase in hepatic arterial flow when injected intra-arterially. The molar ED50 for this hepatic vasodilatation was 40.2 fmol, significantly less than the ED50 for either CGRP or Iso. SP was the most potent hepatic arterial vasodilator yet examined. The vasodilator effect of SP was slightly potentiated by prior beta 2-adrenoceptor blockade. 7. SP caused hepatic arterial vasodilatation when administered by intra-portal injection; its absolute and relative potency was much reduced. 8. SP when injected intra-portally caused a graded increase in hepatic portal inflow resistance. The molar potency for this portal vasoconstriction was significantly greater than that for noradrenaline (NA); however, the maximum increase in portal resistance was significantly less to SP than to NA.9. In view of the location of the peptides CGRP and SP within the afferent innervation of the liver, it is proposed that they play an important function in controlling the hepatic microvasculature in response to sensory stimuli, particularly those arising from changes in portal blood composition secondary to change in metabolic activity within the gastrointestinal tract (GIT).10. Since the peptides are released from the GIT into the hepatic portal inflow, they may modify hepatic arterial blood flow, the extent of which is related to events within the GIT.
摘要
  1. 将两种肽,即降钙素基因相关肽(CGRP)和P物质(SP)分别作为大剂量注射剂,注入麻醉犬的单独灌注的肝动脉和门静脉血管床,以评估它们在这些部位的作用和相对摩尔效力。2. 当经动脉近端注射时,CGRP可使肝动脉血流立即出现剂量相关的增加,这反映了阻力下降。选择性β2肾上腺素能受体拮抗剂ICI 118,551预先给药可使这种血管舒张作用略有增强。3. 按摩尔计算,CGRP作为肝动脉血管舒张剂比非选择性β肾上腺素能受体激动剂异丙肾上腺素(Iso)更有效。4. 门静脉内注射CGRP也可引起肝动脉血管舒张,且无其他心血管变化。5. 门静脉内给药时,高达10 nmol的CGRP对门静脉血管阻力无影响。6. 动脉内注射SP可使肝动脉血流迅速出现剂量相关的增加。这种肝血管舒张的摩尔半数有效量(ED50)为40.2 fmol,明显低于CGRP或Iso的ED50。SP是迄今所检测到的最有效的肝动脉血管舒张剂。预先进行β2肾上腺素能受体阻断可使SP的血管舒张作用略有增强。7. 门静脉内注射SP可引起肝动脉血管舒张;其绝对效力和相对效力均大大降低。8. 门静脉内注射SP可使肝门静脉流入阻力出现分级增加。这种门静脉血管收缩的摩尔效力明显大于去甲肾上腺素(NA);然而,门静脉阻力的最大增加幅度对SP来说明显小于对NA。9. 鉴于肽CGRP和SP在肝脏传入神经支配中的位置,有人提出它们在响应感觉刺激,特别是那些由胃肠道(GIT)内代谢活动变化继发的门静脉血成分变化所引起的感觉刺激时,在控制肝微循环中起重要作用。10. 由于这些肽从GIT释放到肝门静脉流入中,它们可能会改变肝动脉血流,其改变程度与GIT内的事件有关。

相似文献

本文引用的文献

8
Substance P.P物质
Pharmacol Rev. 1983 Jun;35(2):85-141.
10
Sodium receptors activating some nerves of perfused rabbit livers.钠受体激活灌注兔肝脏的一些神经。
Am J Physiol. 1974 Dec;227(6):1273-5. doi: 10.1152/ajplegacy.1974.227.6.1273.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验